News
Introducing SBP-XP™ Immunoconjugates, A Superior and Direct Substitute for HRP
April 19, 2013—Soybean peroxidase (SBP) is a direct substitute for HRP in immunoassays.
SBP provides equal or superior signal compared with HRP, with lower background
Greatly Improved thermostability
“Glow” v “flash” in chemiluminescence
– Low background, high signal
– Less time needed for optimization
– Less need for substrate enhancers
continue→
Fina BioSolutions is recognized by the Rockville Economic Development office for its contributions
March 28, 2013—Fina BioSolutions is recognized by the Rockville Economic Development
office for its contributions.
Andrew Lees will be the course director for the University of Maryland Biotechnology Research and Education Program
March 28, 2013—Andrew Lees, Scientific Director of Fina Biosoutions, will be the course
director for the University of Maryland Biotechnology Research and
Education Program course on downstream processing, June 6-8. For details,
contact Ben Woodard, woodard@umd.edu
Fina Biosolutions Licenses Rights to its Vaccine Conjugation Technology for Development and Manufacturing of PNEUMOCOCCAL vaccines in China to Chengdu Institute of Biological Products Co., Ltd
August 19, 2012—Deal will accelerate development of affordable Pneumococcal Vaccines in China
Rockville, Md. – Fina Biosolutions LLC, a research and development stage biotechnology company focused on developing affordable conjugate vaccines, and The Chengdu Institute of Biological Products Co., Ltd (CDIBP) announced their agreement to license Finabio’s conjugate vaccine technology for the continue→
University of Maryland Center for Vaccine development receives Wellcome Trust grant for a conjugate vaccine using chemistry developed by Andrew Lees, Scientific director of FinaBio Solutions
June 28, 2012—New Vaccine Will Be Fast-Tracked By $4 Million Award from Wellcome Trust
The University of Maryland School of Medicine's Center for Vaccine Development (CVD) has received a $4 million Strategic Translation Award from the prestigious Wellcome Trust to support a collaboration with Bharat Biotech for clinical development of a new conjugate continue→
Andrew Lees will be the course director for Downstream Processing & Protein Purification Workshop
May 2, 2012—Andrew Lees, Scientific Director at Fina BioSolutions is the course director for Downstream Processing & Protein Purification Workshop to be held June 6-8, 2012 at the University of Maryland, College Park, Maryland.
Registration and more information.
Fina BioSolutions presents at MinHai Biotech Beijing and Chengdu Biological Institute on bioconjugation chemistry.
October 19, 2011—Pneumococcal Conjugate Vaccine Symposium. PATH sponsored. Beijing, China
Fina BioSolutions presents at MinHai Biotech Beijing and Chengdu Biological Institute on bioconjugation chemistry.
Andrew Lees will be speaking on Membrane Chromatography for the purification of Conjugate Vaccines.
September 29, 2011—Andrew Lees will be speaking on Membrane Chromatography for the purification of Conjugate Vaccines. Sartorius Downstream Technical Forum, Rockville, MD
Downstream Processing & Protein Purification Workshop
June 8, 2011—Downstream Processing & Protein Purification Workshop
University of Maryland, College Park Biotechnology Research and Education Program
Andrew Lees will be speaking at the IBC 7th Annual Early Development Forum
October 27, 2010—Andrew Lees, Scientific Director of Fina BioSolutions, will be speaking at the IBC 7th Annual Early Development Forum, Preclinical Scale Bioprocessing Meeting, Boston, MA, Nov 1-3, 2010. Membrane Chromatography for the Purification of Conjugate Vaccines.